Brahm M, Balsløv J T, Brammer M, Brun C, Gerstoft J, Jørgensen H E, Kamper A, Larsen S, Lorenzen I, Thomsen A C
Department of Nephrology, Herlev Hospital, Copenhagen, Denmark.
Acta Med Scand. 1988;224(6):605-10.
Thirty-two patients suffering from biopsy-proven glomerulonephritis with proteinuria greater than or equal to 1.2 g/24 hours and/or creatinine clearance less than 50% of normal value were treated for 6 weeks with prednisone plus cyclophosphamide (C+P), azathioprine (A+P) or cyclophosphamide as a monotherapy (C). The effect of the treatment was evaluated after 6 and 16 weeks. The results were entered consecutively in a sequential analysis. The three treatment regimes were compared mutually as well as with the results of 16 weeks' treatment with C and placebo, published previously. Six weeks' treatment with C+P or A+P was superior to C and at least as efficient as 16 weeks' C treatment. C treatment for 6 weeks was less efficient than 16 weeks' C treatment. The side-effects of the 6 weeks' A+P or C+P treatment were fewer and less serious than those reported from the long-term C treatment.
32例经活检证实为肾小球肾炎、蛋白尿大于或等于1.2g/24小时和/或肌酐清除率低于正常值50%的患者,接受了泼尼松联合环磷酰胺(C+P)、硫唑嘌呤(A+P)治疗6周,或环磷酰胺单一疗法(C)。在治疗6周和16周后评估治疗效果。结果连续纳入序贯分析。将三种治疗方案相互比较,并与先前发表的C和安慰剂治疗16周的结果进行比较。C+P或A+P治疗6周优于C,且至少与C治疗16周的疗效相同。C治疗6周的疗效低于C治疗16周。A+P或C+P治疗6周的副作用比长期C治疗报告的副作用更少、更轻。